At present, some therapies based on antisense oligonucleotide (ASOs) have been widely applied in the clinical treatment of muscle diseases, such as Nusinersen, which alters the splicing of SMN2 gene and increases the production of full‐length SMN protein to treat spinal muscular atrophy [111]. Here, SMN2 is linked to spinal muscular atrophy.